Voyager Therapeutics, Inc.
VYGR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13,365 | $5,200 | $6,473 | $6,278 |
| % Growth | 157% | -19.7% | 3.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $13,365 | $5,200 | $6,473 | $6,278 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $35,866 | $31,330 | $31,526 | $35,583 |
| G&A Expenses | $8,093 | $10,495 | $9,640 | $8,994 |
| SG&A Expenses | $8,093 | $10,495 | $9,640 | $8,994 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $43,959 | $41,825 | $41,166 | $44,577 |
| Operating Income | -$30,594 | -$36,625 | -$34,693 | -$38,299 |
| % Margin | -228.9% | -704.3% | -536% | -610.1% |
| Other Income/Exp. Net | $2,785 | $3,258 | $3,709 | $4,396 |
| Pre-Tax Income | -$27,809 | -$33,367 | -$30,984 | -$33,903 |
| Tax Expense | $83 | $15 | $37 | $584 |
| Net Income | -$27,892 | -$33,382 | -$31,021 | -$34,487 |
| % Margin | -208.7% | -642% | -479.2% | -549.3% |
| EPS | -0.47 | -0.57 | -0.53 | -0.59 |
| % Growth | 17.5% | -7.5% | 10.2% | – |
| EPS Diluted | -0.47 | -0.57 | -0.53 | -0.59 |
| Weighted Avg Shares Out | 58,803 | 58,666 | 58,350 | 57,975 |
| Weighted Avg Shares Out Dil | 58,803 | 58,666 | 58,350 | 57,975 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,385 | $2,831 | $3,291 | $3,994 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $932 | $1,065 | $1,014 | $1,011 |
| EBITDA | -$26,877 | -$35,560 | -$33,679 | -$37,288 |
| % Margin | -201.1% | -683.8% | -520.3% | -593.9% |